[Asia Economy Reporter Lee Gwan-joo] Yuyu Pharma announced on the 8th that it has launched 'Senuvela Tablets,' a hyperphosphatemia treatment containing sevelamer.
Senuvela Tablets are a medication that can regulate serum phosphate levels in chronic kidney disease patients whose phosphate excretion is insufficient through diet therapy and dialysis alone.
By launching Senuvela Tablets containing sevelamer, Yuyu Pharma has strengthened its chronic kidney disease-mineral and bone disorder (CKD-MBD) treatment lineup, following its existing calcitriol product Bonki, cinacalcet product Beneph, and paricalcitol product Aplazoo.
CKD-MBD has a global prevalence of 5-8%. Major symptoms include hyperphosphatemia, secondary hyperparathyroidism, and hypocalcemia. Hyperphosphatemia is a condition where phosphate, one of the minerals that make up bones, is elevated above normal levels, weakening bones and increasing the risk of fractures.
A Yuyu Pharma representative said, “The new launch of Senuvela Tablets will provide more diverse treatment options and create an opportunity to gain a competitive edge in the CKD-MBD treatment market. Through Senuvela Tablets, which Yuyu Pharma directly develops, manufactures, and supplies, we aim to become a reliable partner in the treatment of many kidney disease patients.”
The insurance reimbursement price per tablet of Senuvela Tablets has been registered at 510 KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
